Dr. Robert Gabbay Appointed ADA’s Chief Scientific & Medical Officer
By Rhea Teng and Jimmy McDermott
Starting July 1, 2020, Joslin Diabetes Center’s Dr. Robert Gabbay will become the Chief Scientific & Medical Officer of the American Diabetes Association
The American Diabetes Association (ADA) just announced that Dr. Robert Gabbay, MD, PhD has been named the Chief Scientific & Medical Officer (CSMO) of the ADA. He will take this role on July 1, 2020. Dr. Gabbay replaces Dr. William Cefalu, who served as ADA’s CSMO for two and half years before becoming Director of the NIH’s NIDDK Division of Diabetes, Endocrinology, and Metabolic Diseases in August 2019.
Dr. Gabbay is stepping down from a seven-year career as Chief Medical Officer and Senior Vice President of Joslin Diabetes Center to embark on his new journey with the ADA. He brings over 35 years of clinical and research experience with a special emphasis on improving diabetes-related healthcare delivery.
“I’m thrilled and honored,” said Dr. Gabbay when we spoke with him. What is his biggest aim for the next year? “The goal is to improve the lives of all people with diabetes through science and medicine and health care as a whole. All of us working together for one common purpose while we continue to focus on a cure.”
This is incredible news for the ADA – there are so many opportunities for the widely-respected Dr. Gabbay to enable the ADA to lead the diabetes scientific community and to continue to have the premiere scientific journals and annual convening. A hearty congratulations from our entire team at diaTribe! What a triumph for scientists, clinicians, policymakers, and people with diabetes everywhere to have this cutting-edge leader!